Biosimilars so far: Looking back and forward at the patent dance
Natalie Rahhal analyses the patent disputes that have been filed so far around biosimilars and previews what issues to expect this year
After a slow start, litigation over biosimilars is starting
to flourish. A date between Amgen and Sandoz at the Supreme
Court is the headline case but other disputes will also help
shape the parameters of what is expected in patent...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.